On Jan. 07, Huizenga Theodore Alan divested U.S. $562,600 in shares of Ultragenyx Pharmaceutical Inc.. The SVP, Controller, PAO sold 4,000 shares at a price per share of $140.65. The transaction decreased this specific insider’s holdings to 15,716 shares worth around $2.37 million at present.
Wedbush took its Ultragenyx Pharmaceutical Inc. [RARE] rating to the equivalent of a Neutral from an Outperform, and the price target to $110 from $105, in a research note dated December 07, 2020. That figure represents around a -36.9% premium from where the company’s shares closed on Friday. Other analysts also revised their coverage, with Wedbush’s analysts downgrading the shares from “an Outperform” rating to “a Neutral” rating in a research note to investors issued in early December. In addition, there was a downgrade from BofA Securities on November 12, 2020. The rater changed RARE from “a Buy” to “a Neutral”.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Is Ultragenyx Pharmaceutical Inc. [NASDAQ:RARE] a Good Buy Right Now?
It should be noted that RARE technical indicators for short, intermediate as well as long term progress have placed an overall average of 72% as Buy. The average signal changed from 80% Buy in the last week and compares with 100% Buy in the past month. Data from Ultragenyx Pharmaceutical Inc.’s Trend Spotter indicated that the signals were Weakest. The stock current average is 0.65 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 0.56 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.45 million shares.
RARE Price Performance
On Wall Street, Ultragenyx Pharmaceutical Inc. [NASDAQ:RARE] finished Friday’s session up 3.57% at $150.59. The stock went up to $153.155 at the same session while its lowest single day price was $145.41. In the last five days, it saw a rise of about 8.78%, Ultragenyx Pharmaceutical Inc. shares gained by almost 8.78% since the beginning of the year. However, the share price has dropped to as low as -16.17% below its one year high. On 01/08/21, the company shares recorded $153.15, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/06/21, the same year at $131.84. The company’s shares have inclined by 244.36% in the past year. The 50-day SMA achieved is $131.01 while the 200-day SMA is $89.74. Volume gained to 0.92 million from 0.65 million in the previous session.
RARE Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 146.28 level, and in case of violation of this particular level, it will cause more drop to 141.97 level. On the upper level, 157.46 is still the key resistance. The stock may increase to the subsequent resistance at 154.03. The Relative Strength Index (RSI) pinned on the 14-day chart is 55.34, implying a neutral technical stance while the MACD stands at -10.06, meaning price will decrease in the next trading period. Percent R indicator moved to 60.78%, implying low price movement. Stochastic %K at 26.47% suggest holding the stock.
What is the short interest in Ultragenyx Pharmaceutical Inc.?
Short interest in the Ultragenyx Pharmaceutical Inc. stock has surged, increasing by 0.54 million shares to total 6.3 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 6.84 million, data from Yahoo Finance shows. The decrease of -8.57% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 12.69% of the overall float for the stock.
Ultragenyx Pharmaceutical Inc.’s Biggest Shareholders: Who Owns Ultragenyx Pharmaceutical Inc. [RARE]?
Filings by T. Rowe Price Associates, Inc. showed that the firm now holds a total of 8,348,729 shares or roughly 12.62% of the outstanding RARE shares. This means their shares have increased by 682,112 from the 8,348,729 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, Capital Research & Management Co updated stake is worth $804,183,421. Details in the latest 13F filings reveal that Capital Research & Management Co acquired their 1.85% stake valued at $734,704,874 while The Vanguard Group, Inc. added theirs at $614,571,578. During the last quarter, Capital Research & Management Co raised 112,817 of its shares in Ultragenyx Pharmaceutical Inc. while The Vanguard Group, Inc. bought 221,826 shares. The BlackRock Fund Advisors’s holdings currently number 4,149,333 shares at $624848056.47. According to the firm’s last 13F report, Federated Global Investment Manag shares in the company at filing stood at 3,997,800 shares, roughly $473,899,212.
RARE Earnings Forecast For The Current Quarter
Ultragenyx Pharmaceutical Inc. [RARE] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $67.68M and an earnings per share of -$1.15 for Dec 2020. Looking further ahead, the company is expected to report revenue of $70.25M at an EPS of -$1.07 for Mar 2021. The estimates represent upside of 37.00% and -7.80% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
RARE Earnings Estimates For The Current Year
For the financial year, Ultragenyx Pharmaceutical Inc. [NASDAQ:RARE] is expected to bring in revenue of $249.95M. The returns are nearly $146.24 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -3.86, higher than that of FY19 by $3.26. Estimates put this year’s earnings growth at 45.80%, -6.50% for the next, and at an annual 17.20% over the next 5-year period. As for sales, forecasts are for an increase of 141.00% in the current fiscal year and a further 37.00% over the following year.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
What are analyst thoughts on Ultragenyx Pharmaceutical Inc.?
Looking forward to the Ultragenyx Pharmaceutical Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Ultragenyx Pharmaceutical Inc. stock at $123.00 within the next 12 months, which represents almost -22.43 per cent growth from its previous closing price of $150.59. The highest analysts’ target for Ultragenyx Pharmaceutical Inc. stock projections is $185.00 and the lowest one is $64.00. Still, 16 analysts sharing their consensus rating for RARE stock in 2021 agree that it is an Overweight.